Compare Becton Dickinson and Co (BDX) vs Jabil Inc (JBL) Price & Performance

BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.

The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.

JBL trades at $321.96, down 2.52% today, with a bearish technical signal but strong fundamental momentum. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $3.16 exceeding the $3.10 estimate. Revenue growth is robust, projected to rise from $29.80B in 2025 to $33.60B in 2026, driven by AI infrastructure demand. The stock faces near-term pressure but maintains a 50% buy rating from analysts, with a consensus price target of $436.50 suggesting significant upside potential from current levels.

JBL's outlook is supported by AI-driven expansion and solid earnings, but high valuation multiples like a P/E of 40.9 pose risks if growth slows. Competitive pressures in electronics manufacturing and macroeconomic volatility could impact margins. Investors should weigh the strong analyst consensus against technical bearish signals and elevated valuation before committing capital.